Related Experiment Video
Updated: Mar 27, 2026
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Liquidambaris fructus inhibits osteosarcoma through PTGS2/TGFB1 and regulates efferocytosis
Lan Deng1, Mo Jiang2, Chen Zhang3
1Department of Oncology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Jiangxi, China.
Background:
Liquidambaris Fructus can play an anti-tumor role by triggering cell cycle blockade and apoptosis and inhibiting cancer cell proliferation.
Objectives:
To evaluate the effects and potential mechanism of Liquidambaris Fructus on 143B cells and MNNG/HOS CI #5 cells.
Methods:
Cell viability of 143B cells and MNNG/HOS CI #5 cells was evaluated using the CCK-8 assay. A transwell cell migration assay was performed to detect cell migration and invasion. Cell apoptosis was assayed by flow cytometry. Network pharmacology method was used to predict the potential targets and pathway of Liquidambaris Fructus against osteosarcoma. Protein levels were determined using Western blot, while mRNA levels were detected using RT-qPCR analysis. In vitro efferocytosis assay of apop143B-MHSW and apopMNNG-HMDMs was detected by flow cytometry.
Results:
Liquidambaris Fructus can effectively increase 143B and MNNG/HOS CI #5 cell apoptosis levels and inhibit 143B and MNNG/HOS CI #5 cell viability, migration and invasion. Network pharmacology showed that PTGS2 and TGFB1 were two targets related to the enriched efferocytosis pathway. Liquidambaris Fructus inhibited proteins and mRNA of PTGS2 and TGFB1 expression levels in 143B and MNNG/HOS CI #5 cells. Liquidambaris Fructus inhibited PTGS2 and TGFB1 levels in the co-culture of osteosarcoma cells and macrophages. Liquidambaris Fructus inhibited efferocytosis.
Conclusion:
Liquidambaris Fructus can target PTGS2 and TGFB1 to inhibit osteosarcoma cell growth and metastasis, as well as to inhibit efferocytosis, thus alleviating osteosarcoma.
Insights
Liquidambaris Fructus inhibits osteosarcoma cell growth and metastasis by targeting PTGS2 and TGFB1. This traditional remedy also reduces efferocytosis, offering a novel approach to osteosarcoma treatment.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Liquidambaris Fructus exhibits anti-tumor properties by inducing apoptosis and inhibiting cancer cell proliferation.
- Osteosarcoma is a primary bone cancer with significant metastatic potential.
Purpose of the Study:
- To investigate the anti-osteosarcoma effects of Liquidambaris Fructus on 143B and MNNG/HOS CI #5 cell lines.
- To elucidate the underlying molecular mechanisms, including target identification and pathway analysis.
Main Methods:
- Cell viability, migration, invasion, and apoptosis were assessed using CCK-8, Transwell, and flow cytometry assays.
- Network pharmacology identified PTGS2 and TGFB1 as key targets.
- Protein and mRNA expression of PTGS2 and TGFB1 were analyzed via Western blot and RT-qPCR.
- In vitro efferocytosis assays were conducted.
Main Results:
- Liquidambaris Fructus significantly inhibited osteosarcoma cell viability, migration, and invasion while enhancing apoptosis.
- Network pharmacology analysis revealed PTGS2 and TGFB1 as crucial targets within the efferocytosis pathway.
- Liquidambaris Fructus downregulated PTGS2 and TGFB1 expression at both protein and mRNA levels.
- The treatment also inhibited efferocytosis in co-cultures of osteosarcoma cells and macrophages.
Conclusions:
- Liquidambaris Fructus effectively suppresses osteosarcoma progression by targeting PTGS2 and TGFB1.
- The compound's ability to inhibit efferocytosis presents a novel therapeutic strategy for osteosarcoma.
- These findings support the use of Liquidambaris Fructus in alleviating osteosarcoma.
More Related Videos
08:07Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
08:47Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells
Published on: August 21, 2012